A Yap-Myc-Sox2-p53 Regulatory Network Dictates Metabolic Homeostasis and Differentiation in Kras-Driven Pancreatic Ductal Adenocarcinomas
Open accessThe DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Abstract
SUMMARY Employing inducible genetically engineered and orthotopic mouse models, we demonstrate a key role for transcriptional regulator Yap in maintenance of Kras mutant pancreatic tumors. Integrated transcriptional and metabolomics analysis reveals that Yap transcribes Myc, and cooperates with Myc to maintain global transcription of metabolic genes. Yap loss triggers acute metabolic stress, which causes tumor regression while inducing epigenetic reprogramming and Sox2 upregulation in a subset of pancreatic neoplastic cells. Sox2 restores Myc expression and metabolic homeostasis in Yap-deficient neoplastic ductal cells, which gradually re-differentiate into acinar-like cells, partially restoring pancreatic parenchyma in vivo. Both the short-term and long-term effects of Yap loss in inducing cell death and re-differentiation, respectively, are blunted in advanced, poorly differentiated p53 mutant pancreatic tumors. Collectively, these findings reveal a highly dynamic and interdependent metabolic, transcriptional and epigenetic regulatory network governed by Yap, Myc, Sox2 and p53 that dictates pancreatic tumor metabolism, growth, survival, and differentiation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Subramanian, A., Tamayo, P., Mootha, V. K., Mukherjee, S., Ebert, B. L., Gillette, M. A., Paulovich, A., Pomeroy, S. L., Golub, T. R., Lander, E. S., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0506580102 · Cited by 53,625
Genomic analyses identify molecular subtypes of pancreatic cancer
Bailey, P., Chang, D. K., Nones, K., Johns, A. L., Patch, A.-M., Gingras, M.-C., Miller, D. K., Christ, A. N., Bruxner, T. J. C., Quinn, M. C., et al. (2016) · Nature · doi:10.1038/nature16965 · Cited by 3,621 · cited 2×
“Over 70% of human PDACs contain TP53 mutations, which promote PDAC progression into a more aggressive and poorly differentiated basal-like/squamous subtype (Bailey et al., 2016; Hingorani et al., 2005; Vanderas and Papagiannoulis, 2002).”
BackgroundPreinvasive and invasive ductal pancreatic cancer and its early detection in the mouse
Hingorani, S. R., Petricoin, E. F., Maitra, A., Rajapakse, V., King, C., Jacobetz, M. A., Ross, S., Conrads, T. P., Veenstra, T. D., Hitt, B. A., et al. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00309-x · Cited by 2,471
Ryan, D. P., Hong, T. S., & Bardeesy, N. (2014) · New England Journal of Medicine · doi:10.1056/nejmra1404198 · Cited by 2,348 · cited 2×
“Virtually all PDAC tumors carry activating KRAS mutations (Ryan et al., 2014), which are both necessary and sufficient for Murakami et al.”
BackgroundOncogenic Kras maintains pancreatic tumors through regulation of anabolic glucose metabolism
Ying, H., Kimmelman, A. C., Lyssiotis, C. A., Hua, S., Chu, G. C., Fletcher-Sananikone, E., Locasale, J. W., Son, J., Zhang, H., Coloff, J. L., et al. (2012) · Cell · doi:10.1016/j.cell.2012.01.058 · Cited by 2,043
Glutamine supports pancreatic cancer growth through a KRAS-regulated metabolic pathway
Son, J., Lyssiotis, C. A., Ying, H., Wang, X., Hua, S., Ligorio, M., Perera, R. M., Ferrone, C. R., Mullarky, E., Shyh-Chang, N., et al. (2013) · Nature · doi:10.1038/nature12040 · Cited by 1,990
YAP/TAZ at the Roots of Cancer
Zanconato, F., Cordenonsi, M., & Piccolo, S. (2016) · Cancer Cell · doi:10.1016/j.ccell.2016.05.005 · Cited by 1,970 · cited 15×
“Overexpression of YAP has been previously shown to allow KRAS mutant colon cancer cell line HCT-116 to survive KRAS silencing by upregulating the epithelial-mesenchymal transition (EMT) program (Shao et al., 2014).”
BackgroundInfluentialGenome-wide association between YAP/TAZ/TEAD and AP-1 at enhancers drives oncogenic growth
Zanconato, F., Forcato, M., Battilana, G., Azzolin, L., Quaranta, E., Bodega, B., Rosato, A., Bicciato, S., Cordenonsi, M., & Piccolo, S. (2015) · Nature Cell Biology · doi:10.1038/ncb3216 · Cited by 1,219
Aguirre, A. J., Bardeesy, N., Sinha, M., Lopez, L., Tuveson, D. A., Horner, J., Redston, M. S., & DePinho, R. A. (2003) · Genes & Development · doi:10.1101/gad.1158703 · Cited by 1,033
Hippo Pathway Activity Influences Liver Cell Fate
Yimlamai, D., Christodoulou, C., Galli, G. G., Yanger, K., Pepe-Mooney, B., Gurung, B., Shrestha, K., Cahan, P., Stanger, B. Z., & Camargo, F. D. (2014) · Cell · doi:10.1016/j.cell.2014.03.060 · Cited by 857 · cited 1×
“Re-examination of two published microarray datasets including one from our group (Shi et al., 2016; Yimlamai et al., 2014) showed that overexpression of Yap or knockout of Nf2 (a bona fide negative regulator of Yap) significantly downregulated Glul in the mouse liver (Figures S3A–S3B), again contradicting the above-me…”
ResultZhang, N., Bai, H., David, K. K., Dong, J., Zheng, Y., Cai, J., Giovannini, M., Liu, P., Anders, R. A., & Pan, D. (2010) · Developmental Cell · doi:10.1016/j.devcel.2010.06.015 · Cited by 804
Oncogenic Kras is required for both the initiation and maintenance of pancreatic cancer in mice
Collins, M. A., Bednar, F., Zhang, Y., Brisset, J.-C., Galbán, S., Galbán, C. J., Rakshit, S., Flannagan, K. S., Adsay, N. V., & Pasca di Magliano, M. (2012) · Journal of Clinical Investigation · doi:10.1172/jci59227 · Cited by 770 · cited 1×
“We show that Yap ablation, resembling previously reported Kras silencing, causes metabolic crisis and regression of PDAC tumors, which is followed by extensive tissue re-modeling cumulating in partial recovery of acinar parenchyma (Collins et al., 2012; Ying et al., 2012).”
BackgroundKRAS and YAP1 Converge to Regulate EMT and Tumor Survival
Shao, D. D., Xue, W., Krall, E. B., Bhutkar, A., Piccioni, F., Wang, X., Schinzel, A. C., Sood, S., Rosenbluh, J., Kim, J. W., et al. (2014) · Cell · doi:10.1016/j.cell.2014.06.004 · Cited by 744
Yap1 Activation Enables Bypass of Oncogenic Kras Addiction in Pancreatic Cancer
Kapoor, A., Yao, W., Ying, H., Hua, S., Liewen, A., Wang, Q., Zhong, Y., Wu, C.-J., Sadanandam, A., Hu, B., et al. (2014) · Cell · doi:10.1016/j.cell.2014.06.003 · Cited by 716 · cited 2×
“, 2019b) and previous studies establishing Yap as a main resistance mechanism towards Kras inhibition (Kapoor et al., 2014; Shao et al., 2014), our study further ratifies Yap as a true achilles’ heel and compelling target for Kras mutant pancreatic tumors.”
BackgroundModulating the therapeutic response of tumours to dietary serine and glycine starvation
Maddocks, O. D. K., Athineos, D., Cheung, E. C., Lee, P., Zhang, T., van den Broek, N. J. F., Mackay, G. M., Labuschagne, C. F., Gay, D., Kruiswijk, F., et al. (2017) · Nature · doi:10.1038/nature22056 · Cited by 603 · cited 1×
“Rather than feeding into the TCA cycle, Kras mutant PDAC cells divert glucose (Glc) carbon to the pentose phosphate pathway (PPP), hexosamine biosynthetic pathway and serine synthesis pathway (SSP) to support nucleotide biosynthesis and protein glycosylation (Maddocks et al., 2017; Ying et al., 2012).”
BackgroundCooperative Binding of Transcription Factors Orchestrates Reprogramming
Chronis, C., Fiziev, P., Papp, B., Butz, S., Bonora, G., Sabri, S., Ernst, J., & Plath, K. (2017) · Cell · doi:10.1016/j.cell.2016.12.016 · Cited by 555 · cited 1×
“Finally, we confirmed via ChIP-qPCR that Sox2 specifically binds to a previously reported enhancer region and exons 1 and 2 but not the 3’-UTR of the Myc gene in Yap null pancreatic tumor cells (Figure 4K) (Aksoy et al., 2013; cheloufi et al., 2015; Chronis et al., 2017; Deluz et al., 2016; King and Klose, 2017; Kwan…”
MethodMyc Cooperates with Ras by Programming Inflammation and Immune Suppression
Kortlever, R. M., Sodir, N. M., Wilson, C. H., Burkhart, D. L., Pellegrinet, L., Brown Swigart, L., Littlewood, T. D., & Evan, G. I. (2017) · Cell · doi:10.1016/j.cell.2017.11.013 · Cited by 553
AMPK modulates Hippo pathway activity to regulate energy homeostasis
Wang, W., Xiao, Z.-D., Li, X., Aziz, K. E., Gan, B., Johnson, R. L., & Chen, J. (2015) · Nature Cell Biology · doi:10.1038/ncb3113 · Cited by 549 · cited 3×
“These results reveal that rather than regulating a limited numbers of metabolic enzymes as previously reported (Cox et al., 2016; Du et al., 2018; Edwards et al., 2017; Wang et al., 2015), Yap systematically controls the transcriptional programs of multiple metabolic pathways to support nucleotide synthesis.”
BackgroundMethodDefective insulin secretion in hepatocyte nuclear factor 1alpha-deficient mice.
Pontoglio, M., Sreenan, S., Roe, M., Pugh, W., Ostrega, D., Doyen, A., Pick, A. J., Baldwin, A., Velho, G., Froguel, P., et al. (1998) · Journal of Clinical Investigation · doi:10.1172/jci2548 · Cited by 321 · cited 1×
“Endocrine progenitor markers Onecut1, NeuroG3 and NeuroD1 were also upregulated in long-term surviving Yap− cells in vitro and in regenerated KYYF pancreata, although Hnf1a, a transcription factor necessary for maintaining the homeostasis of differentiated endocrine cells (Pontoglio et al., 1998), was largely unaffect…”
BackgroundKing, H. W., & Klose, R. J. (2017) · eLife · doi:10.7554/elife.22631 · Cited by 270 · cited 1×
“Finally, we confirmed via ChIP-qPCR that Sox2 specifically binds to a previously reported enhancer region and exons 1 and 2 but not the 3’-UTR of the Myc gene in Yap null pancreatic tumor cells (Figure 4K) (Aksoy et al., 2013; cheloufi et al., 2015; Chronis et al., 2017; Deluz et al., 2016; King and Klose, 2017; Kwan…”
MethodA p53 Super-tumor Suppressor Reveals a Tumor Suppressive p53-Ptpn14-Yap Axis in Pancreatic Cancer
Mello, S. S., Valente, L. J., Raj, N., Seoane, J. A., Flowers, B. M., McClendon, J., Bieging-Rolett, K. T., Lee, J., Ivanochko, D., Kozak, M. M., et al. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.09.007 · Cited by 179 · cited 2×
“P53 deficiency was recently reported to further activate Yap in Kras mutant PDAC through suppression of a negative regulator - Ptpn14 (Mello et al., 2017).”
Background
Cited by
Wang, S., Zheng, Y., Yang, F., Zhu, L., Zhu, X.-Q., Wang, Z.-F., Wu, X.-L., Zhou, C.-H., Yan, J.-Y., Hu, B.-Y., et al. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00659-4 · Cited by 369
Insights into recent findings and clinical application of YAP and TAZ in cancer
Franklin, J. M., Wu, Z., & Guan, K.-L. (2023) · Nature Reviews Cancer · doi:10.1038/s41568-023-00579-1 · Cited by 213
TEAD Inhibition Overcomes YAP1/TAZ-Driven Primary and Acquired Resistance to KRASG12C Inhibitors
Edwards, A. C., Stalnecker, C. A., Jean Morales, A., Taylor, K. E., Klomp, J. E., Klomp, J. A., Waters, A. M., Sudhakar, N., Hallin, J., Tang, T. T., et al. (2023) · Cancer Research · doi:10.1158/0008-5472.can-23-2994 · Cited by 91
McCubrey, J. A., Yang, L. V., Abrams, S. L., Steelman, L. S., Follo, M. Y., Cocco, L., Ratti, S., Martelli, A. M., Augello, G., & Cervello, M. (2022) · Cells · doi:10.3390/cells11142155 · Cited by 49
“YAP has been shown to promote keys events in KRas-mediated pancreatic cancer tumorigenesis, namely: growth, drug resistance, metabolic reprogramming, differentiation, EMT and metastasis [83,84].”
BackgroundYu, T., Liu, Y., Xue, J., Sun, X., Zhu, D., Ma, L., Guo, Y., Jin, T., Cao, H., Chen, Y., et al. (2022) · Cell Death Discovery · doi:10.1038/s41420-022-01104-3 · Cited by 15
Metadata
- Authors
- Murakami, S., Nemazanyy, I., White, S. M., Chen, H., Nguyen, C. D. K., Graham, G. T., Saur, D., Pende, M., & Yi, C.
- Venue
- Developmental Cell
- Publisher
- Elsevier BV
- Published
- 2019-10
- Volume
- 51
- Issue
- 1
- Pages
- 113-128.e9
- ISSN
- 1534-5807 (ISSN-L)
- OpenAlex
- W2969275797
- Cited by
- 83
- References
- 21
- FWCI
- 5.10
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.